Durect Corporation - Asset Resilience Ratio
Durect Corporation (DRRX) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Durect Corporation PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Durect Corporation's Asset Resilience Ratio has changed over time. See Durect Corporation net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Durect Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Durect Corporation market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Durect Corporation maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Durect Corporation Industry Peers by Asset Resilience Ratio
Compare Durect Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Durect Corporation (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Durect Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.32% | $792.00K | $18.35 Million | +1.48pp |
| 2023-12-31 | 2.83% | $1.28 Million | $45.19 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $60.10 Million | -- |
| 2021-12-31 | 21.70% | $19.97 Million | $91.99 Million | -3.97pp |
| 2020-12-31 | 25.68% | $19.42 Million | $75.64 Million | -8.91pp |
| 2019-12-31 | 34.58% | $29.75 Million | $86.02 Million | +29.24pp |
| 2018-12-31 | 5.34% | $2.67 Million | $50.00 Million | -8.56pp |
| 2017-12-31 | 13.90% | $7.38 Million | $53.11 Million | -34.48pp |
| 2016-12-31 | 48.39% | $19.60 Million | $40.51 Million | -6.04pp |
| 2015-12-31 | 54.43% | $25.46 Million | $46.77 Million | -5.50pp |
| 2014-12-31 | 59.93% | $30.02 Million | $50.08 Million | +28.69pp |
| 2013-12-31 | 31.24% | $12.75 Million | $40.82 Million | -6.50pp |
| 2012-12-31 | 37.74% | $17.34 Million | $45.94 Million | -2.71pp |
| 2011-12-31 | 40.45% | $19.90 Million | $49.20 Million | -11.46pp |
| 2010-12-31 | 51.91% | $35.07 Million | $67.56 Million | -4.55pp |
| 2009-12-31 | 56.46% | $32.83 Million | $58.15 Million | +28.64pp |
| 2008-12-31 | 27.83% | $20.84 Million | $74.87 Million | +4.37pp |
| 2007-12-31 | 23.46% | $19.71 Million | $84.02 Million | -4.15pp |
| 2006-12-31 | 27.61% | $28.30 Million | $102.48 Million | +12.26pp |
| 2005-12-31 | 15.35% | $18.02 Million | $117.41 Million | -10.12pp |
| 2004-12-31 | 25.47% | $21.77 Million | $85.47 Million | -9.68pp |
| 2003-12-31 | 35.15% | $39.51 Million | $112.41 Million | -4.20pp |
| 2002-12-31 | 39.35% | $28.71 Million | $72.97 Million | -1.26pp |
| 2001-12-31 | 40.60% | $42.61 Million | $104.94 Million | -7.26pp |
| 2000-12-31 | 47.86% | $57.73 Million | $120.61 Million | -8.83pp |
| 1999-12-31 | 56.69% | $12.73 Million | $22.46 Million | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more